Novavax, Inc. (NASDAQ:NVAX) [Trend Analysis] retains strong position in active trade, as shares scoring 5.09% to $5.78 in a active trade session, while looking at the shares volume, around 10.37 Million shares have changed hands in this session. Novavax (NVAX) announced that the FDA has granted Fast Track Designation to its’ RSV F-Protein nanoparticle vaccine candidate for the protection of older adults. The firm announced that the FDA has granted Fast Track Designation to Novavax’ RSV F-Protein nanoparticle vaccine candidate for the protection of older adults (60 years of age and older).
“We fully enrolled the Resolve Phase 3 clinical trial of our RSV F Vaccine in 11,850 older adults in December 2015. The primary efficacy objective of the Resolve trial is the prevention of moderate-severe RSV-associated lower respiratory tract disease, as defined by the presence of multiple lower respiratory tract symptoms.” The firm has institutional ownership of 84.30%, while insider ownership included 0.20%. NVAX attains analyst recommendation of 1.60 with week’s performance of 12.23%. Investors looking further ahead will note that the Price to next year’s EPS is 4.20%.
Novartis AG (NYSE:NVS) [Trend Analysis] knocking active thrust in leading trading session, shares an advance of 1.89% to 79.90 with around 2.25 Million shares have changed hands in this session. Ensemble Therapeutics announced that Novartis (NVS) has acquired rights to expand its access to Ensemble’s interleukin-17 antagonist program, which was previously advanced as a joint collaboration between the two companies. Ensemble has completed its contributions to this program and Novartis will now continue further activities independently. The financial terms of the transaction are not disclosed The stock is going forward its fifty-two week low with 16.02% and lagging behind from its 52-week high price with -22.30%.
Likewise the positive performance for the quarter recorded as 10.09% and for the year was -19.82%, while the YTD performance remained at -3.52%. NVS has Average True Range for 14 days of 1.13.
Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) [Trend Analysis] swings enthusiastically in regular trading session, it an advance of 26.63% to close at $23.35. Sarepta Therapeutics announced that the FDA will not complete its review of the Eteplirsen New Drug Application by the PDUFA date (SRPT). The firm announced that the FDA has notified it that they are continuing their review and internal discussions related to our pending NDA for eteplirsen and will not be able to complete their work by the Prescription Drug User Fee Act goal date of May 26, 2016.
The FDA has communicated that they will continue to work past the PDUFA goal date and strive to complete their work in as timely a manner as possible. SRPT: experts calculate Return on Investment of -103.00%. The stock is going forward its fifty-two week low with 191.88% and lagging behind from its 52-week high price with -44.37%. SRPT last month stock price volatility remained 10.33%.